$Novo Nordisk AS(NVO.US) 由於減肥神藥 Wegovy 與 Ozempic 的「驚艷」效果，在 2023 年上半年營業收入和歸屬淨利增速雙增 30%，營收來到 1,077 億丹麥克朗，同時諾和諾德 (NVO) 上調全年營收成長從預期的 27~33% 上調至 32~38%；在消息發出後，該藥廠 13 日股價連四漲，市值突破 4,600 億美元大關，比前歐洲市值龍頭 LVMH 高出千億美元。
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.